Erosive Pustular Dermatosis of the ScalpSymptoms, Doctors, Treatments, Advances & More
Learn About Erosive Pustular Dermatosis of the Scalp
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Susan Chon is a Dermatologist practicing medicine in Houston, Texas. Dr. Chon is rated as an Elite provider by MediFind in the treatment of Erosive Pustular Dermatosis of the Scalp. She is also highly rated in 10 other conditions, according to our data. Her clinical expertise encompasses Erosive Pustular Dermatosis of the Scalp, Actinic Keratosis, Lymphocytic Infiltrate of Jessner, and Basal Cell Skin Cancer. Dr. Chon is currently accepting new patients.
Minars Dermatology
Ran Huo is a Dermatologist practicing medicine in Hollywood, Florida. He has been practicing medicine for over 17 years. Dr. Huo is rated as an Advanced provider by MediFind in the treatment of Erosive Pustular Dermatosis of the Scalp. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Syringoma, Syringocystadenoma Papilliferum, Sebaceous Adenoma, and Spirurida Infections. Dr. Huo is board certified in American Board Of Dermatology.
Robert Kirsner is a Dermatologist practicing medicine in Miami, Florida. Dr. Kirsner is rated as an Advanced provider by MediFind in the treatment of Erosive Pustular Dermatosis of the Scalp. He is also highly rated in 16 other conditions, according to our data. His clinical expertise encompasses Pyoderma Gangrenosum, Livedo Reticularis, Stasis Dermatitis and Ulcers, and Cutaneous T-Cell Lymphoma (CTCL). Dr. Kirsner is currently accepting new patients.
Summary: Continuation of the CARRA Registry as described in the protocol will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including safety questions.